Company intelligence / Profile preview

Infinity Pharmachem

Cambridge, Massachusetts, United Statesinfiniumpharmachem.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Infinity Pharmaceuticals developed small molecule therapeutics targeting PI3K-gamma, with its lead candidate IPI‑549 evaluated as monotherapy and combination therapy across several oncology indications. The company filed for bankruptcy in October 2023 after years of development activity. No recent clinical results are available post-bankruptcy.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Collaborations with other biopharma companies were mentioned but not specifically named in current sources. Past partnerships included Takeda and others.

Beyond the preview

Go deeper on Infinity Pharmachem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infinity Pharmachem.

Explore the full profile